Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers

Designed with the help of artificial intelligence to recognize multiple genetic features of each patient's tumor, a small clinical trial of a personalized therapeutic vaccine has shown durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine also prevented relapse in some patients.  At the AACR Annual Meeting 2024, Olivier Lantz, MD, PhD, Head of the Clinical Immunology Laboratory at the Institut Curie Hospital in Paris, reported data using a "neoantigen-based vaccine" specifically designed to recognize multiple genetic features unique to each patient's tumor. During the conference, Lantz called into the OncTimesTalk studio to tell Peter Goodwin about the clinical options that could develop from such highly personalized vaccines.